Interferon (IFN)-a is involved in the pathogenesis of systemic lupus erythematosus. Studies in murine lupus models have revealed that type I IFN exerts either a protective effect in MRL/lpr, or can detrimentally impact disease progression, as in NZB/ W mice. To understand this paradox, we examined the kinetic global gene expression in pre-autoimmune NZB/W-, MRL/lprand normal BALB/c-derived splenic mononuclear cells following ex vivo IFN-a treatment. Analysis of IFN-a-induced gene expression patterns revealed genes associated with antiproliferative activity of IFN-a including CDKN1A, GADD45B, pituitary tumor-transforming 1, SCOTIN, ataxia telangiectasia-mutated homolog and calcyclin-binding protein were upregulated in MRL/ lpr and/or BALB/c mice. Of IFN-a-induced genes differentially expressed in NZB/W vs BALB/c and MRL/lpr mice at 3 h time point, enhanced expression of CCND1, cyclin D2, matrix metalloproteinase 13 and a panel of cytokines and chemokines and impaired expression of negative inflammatory regulators CD69 and an Src family kinase hemopoietic cell kinase were notable. Interestingly, the splenic mononuclear cells from the NZB/W not MRL/lpr lupus-prone mice at the pre-autoimmune stage before ex vivo IFN-a treatment, have increased expression of many known IFN-regulated genes. These results provide a unique genomic view of ex vivo IFN-a response in two lupus-prone models, and help to have an insight into the role of IFN-a in lupus pathogenesis Genes and Immunity (2007) 
Introduction
Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by a break of immune tolerance to self antigens, resulting in inflammation and damage to a range of organ systems. The exact pathoetiology of SLE remains elusive. Elevated serum levels of IFN-a have long been observed and correlated with disease activity. A series of studies using microarray gene expression analysis in patient peripheral blood cells demonstrated an 'IFN signature' in SLE, which correlated with renal and hematological involvement of phenotypes. [1] [2] [3] [4] [5] [6] Supporting evidence has also come from studies on murine lupus. The (New Zealand Black (NZB) Â New Zealand White (NZW))F1 hybrid female mice (NZB/W) develop a disease closely resembling human SLE, characterized by the production of antinuclear antibodies, severe glomerulonephritis and early mortality. In the NZB parental strain, which also develops a lupus-like syndrome, homozygous IFN-a/b R-deleted NZB mice had significantly reduced antierythrocyte autoantibodies, erythroblastosis, hemolytic anemia, anti-DNA autoantibodies, kidney disease and mortality. 7 In contrast to normal BALB/c mice, continuous in vivo treatment of IFN-a in pre-autoimmune NZB/W mice from 8 weeks of age precipitates the autoimmune process and kidney damage, leading to premature death from severe immune complex glomerulonephritis. This result provides a direct evidence that IFN-a is implicated in the pathogenesis of SLE. 8 Thus, the type I IFNs have emerged as a dominant target in the pathogenesis of SLE.
However, a study of congenic lupus-prone MRL/ CD95lpr/lpr (MRL/lpr) mice, which lack the type I IFN receptor or both type I and type II IFN receptors, arrived at countering conclusions. Deficiency of the type I IFN-R surprisingly worsened lymphoproliferation, autoantibody production and end-organ disease, thus demonstrating that type I IFN exerted a protective effect on MRL/lpr mice. 9 Initiating IFN-b treatment in MRL/lpr mice with mild and advanced disease highly effective in prolonging survival and ameliorating the clinical (renal function, proteinuria, splenomegaly and skin lesions), serologic (autoantibodies and cytokines) and histologic parameters of the lupus-like disease; 10 however, IFN-a has been demonstrated to play a role in the disease pathogenesis in MRL/lpr mice by inducing the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential, which could be responsible for a chronic, nonantigenspecific autoimmune attack on organs expressing low levels of Fas. 11 MRL/lpr mice, in susceptible genetic backgrounds, such as MRL, exhibit a lymphoproliferative disorder that evolves into severe systemic autoimmunity due to defective Fas-induced death. 12 The initiation of SLE is considered to be the effect of many environmental triggers acting on individuals predisposed towards SLE. IFN-a-based treatments are widely used for viral hepatitis and carcinoid tumors; however, several case reports have emerged describing autoimmune conditions that have developed during IFN-a therapy. [13] [14] [15] These observations in human and murine lupus implicate a complicated role of the type I IFN involved in lupus pathogenesis. We hypothesize that inappropriate activation of type I interferon (IFN) signaling pathways, combined with a genetic predisposition, may be important in SLE pathogenesis. To test this hypothesis and explore the molecular mediators underlying the acceleration of lupus phenotype in NZB/ W not BALB/c mice by continuous in vivo IFN-a treatment from 8 weeks of age (Mathian Alexis et al. 8 study), we performed oligonucleotide microarray (Illumina, San Diego, CA, USA) kinetic analysis of mRNA expression changes in the pre-autoimmune NZB/W and MRL/lpr lupus-prone mice-derived splenic mononuclear cells following ex vivo IFN-a treatment and using BALB/c mice as a normal control. MRL/lpr mice exhibit signs of B-cell activation and serum autoantibodies at approximately 6 weeks of age and half the mice will die of glomerulonephritis by 6 months of age. 16 In female NZB/W mice, beginning at the age of B3-4 months, autoantibodies, including anti-DNA antibodies, are developed and, by 7-8 months, immune complex deposits form in the kidneys. Mice die of the disease within 1 year. 17 In this study, MRL/lpr mice (females, 4-5 weeks of age), NZB/W mice (females, 8 weeks of age) and BALB/c mice (females, 8 weeks of age) were used. For both lupus-prone murine models, serum IgG doublestranded DNA antibody titers at the time of ex vivo IFN-a stimulation were assayed to assure these mice in the preautoimmune state. Through the global analysis of signaling pathways, we observed that several genes implicated in p53 signaling pathway and associated with the antiproliferative activity of IFN-a were upregulated in MRL/lpr and BALB/c not NZB/W mice. By comparing the expression of IFN-stimulated genes (ISGs) in signal intensities, a series of genes associated with inflammation and proliferation were found to be overexpressed in NZB/W mice. Notably, a significant IFN-aresponsive gene-expression signature in the absence of IFN-a treatment in vitro was identified in pre-autoimmune NZB/W mice at 8 weeks of age, but not in 4-to 5-week-old lpr and normal BALB/c mice. Of these genes, we propose that a panel of chemokines and cytokines, especially CXCL10, as molecular mediators of IFN-a action, might play an important role in disease development and exacerbation in genetically susceptible, preautoimmune NZB/W mice.
Results
Profiling IFN-a-inducible gene expression in the preautoimmune NZB/W-, MRL/lpr-and BALB/c mice-derived splenic mononuclear cells, respectively As we focused on the primary IFN-a response genes, changes in gene expression after 3 h ex vivo IFN-a treatment relative to the untreated control culture in each strain were first assessed using BeadStudio software (Figure 1a) , 2115, 1429 and 981 genes and expressed sequence tags (ESTs) whose mRNA expression levels changed significantly (Po0.01) after 3 h IFN-a stimulation were identified in BALB/c-, MRL/lpr-and NZB/Wderived splenic mononuclear cells, respectively. The expression of about half of these genes and ESTs changed less than twofold in each strain. The expression that changed more than five, three and twofold was 205, 379 and 766, respectively, for BALB/c; 191, 330 and 584 for MRL/lpr; and 28, 161 and 418 for NZB/W mice. To increase the reliability of our microarray data and to optimize the experimental procedure and validation method, genes that met both of the following criteria in three strains respectively were identified as IFN-aregulated: (1) P-values o0.01 analyzed by the BeadStudio software for the difference in expression level relative to the untreated control; and (2) greater than a twofold change when compared with untreated control. We extracted a common set of 315 transcripts modulated in all three strains, 166 transcripts induced in both BALB/c and MRL/lpr mice, as well as a set of 288, 119 and 74 transcripts uniquely induced in BALB/c, MRL/lpr and NZB/W mice, respectively (Figure 1b) .
Second, comparison of the difference in gene-expression level between different strains were performed. The following criteria were applied to generate genes that were differentially expressed between either two strains including NZB/W with respect to MRL/lpr; NZB/W with respect to BALB/c; and MRL/lpr with respect to BALB/c and three subsets of genes which expressed differentially in either strain with respect to the other two strains at 3 h time point were extracted; (1) P-values o0.01; (2) X1.5-fold difference in gene-expression level. Of these differential-expressing genes between different strains, we focused on the difference in expression level of IFN-a-regulated genes.
The expression of these genes at the 6 and 24 h time points were tracked. Comparison of the gene expression at different time points in different strains was performed on normalized data.
IFN-a-induced genes involved in signaling pathways
There was a major subset of signaling molecules increased concomitantly following IFN-a treatment in all three strains, as well as a subset of signaling molecules uniquely induced in the three strains. We used the pathway analysis software CRSD (a comprehensive web server for composite regulatory signature discovery) to investigate the global effect of IFN-a on the signaling pathways regulated in NZB/W and MRL/lpr mice respectively. The top 17 signal pathways were summarized in Table 1 . The signaling pathways shared between the three strains with Po0.001 were mainly composed of the Toll-like receptor signaling pathway, Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway, IFN-a and MAPKinase signaling pathway, IL-2 receptor b chain in T-cell activation, cytokine network, antigen processing and presentation and regulation of transcriptional activity by promyelocytic leukemia (PML). Several genes related to the Prion Pathway and Prion disease, antisense pathway, Ahr signal transduction pathway and Porphyrin and chlorophyll metabolism were induced only in BALB/c mice. Figure 2 illustrated a subset of genes involved in the above-mentioned signaling pathways. The complex crosstalk among multiple signaling molecules and involved pathways underlying IFN-a treatment were suggested. Of a panel of cytokines and chemokines induced in all three strains, MIP-1a and MCP-5 (CCL12), ATAC(XCL1), CXCL10 (IP10), IL15 and IL10 were significantly overexpressed in NZB/W vs MRL/lpr and BALB/c mice. It has been reported that IFN-a priming confers a proinflammatory gain of function effect on IL-10, leading to IL-10-induced expression of IRF1, CXCL9 and CXCL10 that may contribute to its pathogenic role in SLE. 18 Chemokines MIP-1a (CCL3), MIP-1b (CCL4), RANTES (CCL5) and ATAC were known not only as chemoattractants but also as coactivators of macrophages, constituting together with IFN-g a group of type 1 cytokines to act as a functional unit, used by NK cells and CD8 þ T cells in the immune defense. 19 To validate further the enhanced proinflammatory expression pattern induced by IFN-a predominantly in NZB/W mice detected by microarray, the time course of expression levels of IP10, XCL1, MIP1-a and IL-15 in three strains were assessed by real-time PCR and thereby confirming the microarray data ( Figure 3 ).
Effects on cell growth and death
As auto-reactive T-and B-cell activation and proliferation play key roles in the development of the lupus syndrome, genes involved in apoptosis and cell-cycle regulation induced by IFN-a in the three strains were summarized in Table 2 . The common and uniqueinduced proapoptotic genes in three strains mirrored the activation of diverse apoptosis-related signaling pathways. Analysis using CRSD software highlighted several apoptosis-related signaling pathway headings, including regulation of transcriptional activity by PML in all three strains; the D4-GDI signaling pathway, role of mitochondria in apoptotic signaling and caspase cascade in apoptosis in NZB/W mice; and the ceramide signaling pathway in BALB/c and lpr mice. The Fas signaling pathway was shared by NZB/W and BALB/c, but not MRL/lpr mice, verifying the accuracy of this pathway analysis system (Figure 2) .
Progression through the cell cycle is regulated by cyclin/cyclin-dependent kinase (CDK) complexes and CDK inhibitors. Cyclin D2 (CCND2) in complex with CDK4 or CDK6 phosphorylates retinoblastoma family proteins, thereby causing the de-repression of E2F transcription to promote G 1 /S cell-cycle transition.
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CCND2 was upregulated in three strains and CCND1 was upregulated in two lupus-prone mice, both of two D-type cyclins overexpressed in NZB/W mice. Schlafen family members SLFN1, SLFN2 and SLFN8 and retinoblastoma family retinoblastoma-like 1 (p107) are negative cell-cycle regulators found to be upregulated in three strains. Several genes related to the p53 signaling pathway were transcriptionally upregulated in BALB/c and/or MRL/lpr, but not in NZB/W mice. These included pituitary tumor-transforming 1 (PTTG1), ataxia telangiectasia-mutated homolog, calcyclin-binding protein (CACYBP) and the p53-targeted genes, cyclindependent kinase inhibitor CDKN1A (p21 WAF1 ), SCOTIN and growth arrest and DNA-damage-inducible 45 b (GADD45B). The tumor suppressor protein p53 is a wellknown transcription factor that induces growth arrest or apoptosis in response to cellular stress. PTTG1 was identified as a transcriptional activator of the p53 signaling pathway and causes p53-dependent and -independent apoptosis. 21, 22 Ataxia telangiectasia-mutated homolog as one of the master modulators of the cell-cycle checkpoint signaling pathways are required for regulation of a wide variety of downstream proteins, including the tumor suppressor protein p53. 23 Calcyclinbinding protein (SIP) as a ubiquitin E3 ligase component of the p53-induced b-catenin degradation pathway functions as an essential checkpoint for cell-cycle progression.
24 CDKN1A binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes to induce G 1 -phase arrest. 25, 26 GADD45-b negatively regulates cell growth by interacting with cdc2 and cyclin B, thus causing G 2 /M cell-cycle arrest. 27 Both p21 WAF1 and GADD45-b have been appointed a functional role in mouse lupus development. [28] [29] [30] CDKN1A and PTTG1 was selected and the difference in fold induction between two lupusprone mice was confirmed by real-time PCR (Figure 3 ). These data suggest that two lupus-prone models differ in their response to the antiproliferative activity of IFN-a, which is interesting given the protective role that IFN-a may have in the MRL/lpr model. ISGs in three strains respectively were analyzed with the CRSD software based on KEGG and Biocarta data base. Shown are the top 17 signal pathways in three strains respectively. All genes upregulated by IFN-a involved in above signal pathways met the criteria of Po0.01 with more than twofold change in signal intensities (see details in Figure 2 ).
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Global analysis of lupus mice treated by IFN-a in vitro Q Lu et al
ISGs differentially expressed at the 3 h time point in NZB/W vs MRL/lpr and BALB/c mice In Figure 4a , among ISGs which was shared by three strains and overexpressed in NZB/W mice, CXCL10 was notable with a 4.5-fold difference in signal intensities compared to lpr and a 3.2-fold change compared to BALB/c at 3 h time point. Others mainly included IL-15, CCND1, CCND2, cyclin-dependent kinase-like 2 (CDKL2), secretin (SCT), a gastrointestinal peptide also recently substantiated as a neuron peptide. IL-15 resembles IL-2 in its biological activities, stimulating T-cell and NK-cell proliferation and activation as well as enhancing B-cell expansion and Ab production.
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CCND2 was, in part, induced by the 'IL-2 receptor b chain in T-cell activation signaling pathway', which enables cells to progress from G 1 to S phase to promote T-cell proliferation. 32 Cbp/p300-interacting transactivator CITED2, microtubule-associated protein 7 (MTAP7), matrix metalloproteinase-13 (MMP-13) and cysteine-rich motor neuron 1 (CRIM1) were induced and overexpressed in a unique way in the NZB/W mice. MMP-13 is responsible for type II collagen degradation, which has an obvious role in the joint tissue destruction that is a major feature of inflammatory joint diseases such as rheumatoid arthritis and osteoarthritis. 33 CITED2 interacts with the ubiqui- Figure 2 ISGs within the signal transduction network. IFN-a-inducible gene-expression profiles in the three strains were subjected to signaling pathway analysis using the CRSD software. The expression of ISGs involved in signaling pathways were visualized with the software HCE 3.0. The input data were transformed as described in Materials and methods. ISGs, IFN-stimulated genes.
Global analysis of lupus mice treated by IFN-a in vitro Q Lu et al tously expressed transcriptional co-activators CBP/p300, which have the histone acetyltransferase activity and participate in the activity of hundreds of different transcription factors, including STATs. 34, 35 Both real-time PCR and microarray agreed, indicating a transient upregulation pattern of expression unique in NZB/W mice, which peaked at 3 h IFN-a stimulation for CITED2 (Figure 3 ). The glandular kallikrein gene family KLK5, KLK27 and kallikrein 1-related peptidase b4 (KLK1B4, NGFA), and IFN-induced transmembrane protein 2 (IFITM2) were identified initially as primary responsive genes in BALB/c and MRL/lpr mice at the 3 h time point, however, maximal induction of KLK5, KLK27, KLK1B4, IFITM2 were seen at 6 h in all three strains and shown significant overexpression in NZB/W mice. The glandular kallikrein gene family encodes specific proteases involved in the processing of biologically active peptides. OAS (2 0 -5 0 oligoadenylate synthetases) are a group of enzymes involved in antiviral response. Interestingly, expression of OAS1G and OAS1C (OASL2) mRNA were induced by IFN-a stimulation at 3 h and peaked at 6 h in both lupus-prone mice but were unaffected in IFN-a-treated splenic mononuclear cells from BALB/c mice.
Ubiquitin-specific protease 25 (Usp25), N-myc (and STAT) interactor (NMI), histocompatibility 2, T-region locus 23 (H2-T23), IFN-activated gene 203 (IFI203), IFNinduced protein 44 (IFI44), CD69, lymphocyte antigen 6 complex LY6C, 5-nucleotidase, cytosolic III (NT5C3) and membrane-spanning 4-domains, subfamily A, member 4C (MS4A4C) were upregulated by IFN-a in all three strains, but displayed lower expression levels in NZB/W mice compared to BALB/c and MRL/lpr mice at 3 h. CD69 was reported to play a key role in decline of autoimmune reactivity and inflammation by synthesis of TGF-b, using a model of collagen-induced arthritis (CIA) in WT and CD69-deficient mice. 36 A member of the Src family of tyrosine kinase HCK (hemopoietic cell kinase) was upregulated by IFN-a with 5.2-fold in BALB/c, 2.4-fold in MRL/lpr and 1.5-fold in NZB/W mice, and overexpressed in BALB/c and MRL/lpr mice significantly at 3 h time point comparing to NZB/W mice. Using hck-/-fgr-/-mice, HCK has been demonstrated as a downregulator of myeloid cell chemokine signaling by maintaining the tonic phosphorylation of paired-Ig-like receptor B (PIR-B). 37 ISGs differentially expressed at the 3 h time point in lpr vs BALB/c and NZB/W mice In Figure 4b , ISGs that were overexpressed in lpr vs BALB/c and NZB/W mice could be grouped into five major families: (1) immune response (lymphocyte anti- Global Gene expression was measured with oligonucleotide microarrays performed on normalized data. Data represent genes involved in apoptosis and cell-cycle regulation, whose expression was differentially induced with more than twofold by IFN-a and peaked at 3 h time point in splenic mononuclear cells of either strain with Po0.01 (BeadStudio software). Global analysis of lupus mice treated by IFN-a in vitro Q Lu et al gen 6 complex LY6F, LY6D, IFN-induced with helicase C domain 1 (IFIH1)); (2) complement and coagulation (complement factor B (H2-BF) and fibrinogen-like protein 2 (FGL2)); (3) metabolism (histidine decarboxylase (HDC), transporter solute carrier family 25, member 12 (SLC25A12) and xanthine dehydrogenase (XDH)); (4) growth-regulated (SLFN4 and maternal embryonic leucine zipper kinase (MELK)); and (5) miscellaneous (Phosphatase INPP5B, transcription activator nucleosome-binding protein 1 (NSBP1) and cysteine-type endopeptidase Rhesus blood group-associated A glycoprotein (RHAG)). Serine peptidase inhibitor, clade A, member 3F (SERPINA3F), SLFN8, guanylate nucleotide-binding protein (GBP) 6, Z-DNA-binding protein 1 (ZBP1), suppressor of cytokine signaling 3 (SOCS3), IFN-induced protein 35 (IFI35) and tryptophanyl-tRNA synthetases (WARs) showed lower expression levels in MRL/lpr compared to BALB/c and NZB/W mice at the 3 h time point; all of these genes were upregulated by IFN-a treatment in all three strains. Amyotrophic lateral sclerosis 2 (juvenile) homolog (human) (ALS2) and histocompatibility 2 (H2)-Q7 were induced in MRL/lpr, showing lower expression level compared to the other two strains.
ISGs differentially expressed at the 3 h time point in BALB/c vs lpr and NZB/W mice In Figure 4c , ISGs overexpressed in BALB/c mice could be grouped into four major families: (1) immune response (GBP1, GBP5); (2) transcription factor (zinc finger, CCHC domain-containing ZCCHC11, aryl hydrocarbon receptor nuclear translocator (ARNT) and growth arrest and DNA-damage-inducible 45 b(GADD45b)); (3) metabolism-regulated (phosphoglycerate mutase 1(PGAM1), and carboxypeptidase A3, mast cell (CPA3)); (4) apoptosis regulators (granzyme A (GZMA) and heat-shock 70 kDa protein 1B (HSPA1B)); and (5) actin cytoskeleton organization and biogenesis (thymosin, b 10 (TMSB10) and cysteine and glycine-rich protein 1 (CSRP1)); (6) miscellaneous (RNA polymerase 1-3 (RPO1-3), cytotoxic T lymphocyte-associated protein 2 a (CTLA2A)).
IFN-induced protein with tetratricopeptide repeats 3 (IFIT3), torsin A-interacting protein 2 (TORIAP2), guanine nucleotide-binding protein, b 4(GNB4), gene model 440(GM440), neuron-specific gene family member 2 (NSG2) and macrophage-expressed gene 1(MPEG1) were commonly induced in all three strains, but were expressed at a lower level in BALB/c compared to the other two strains. Cathepsin E (CSTE) and histocompatibility 2, K region locus 1 (H2-K1) were induced in BALB/c mice. H2-K1 showed significantly lower expression level compared to the other two strains.
IFN signature in pre-autoimmune NZB/W mice at 8 weeks of age Of the 311 transcripts that were identified as differentially expressed genes in splenic mononuclear cells of pre-autoimmune NZB/W mice at 8 weeks of age compared to 4 to 5-week-old lpr mice and 8-week-old BALB/c mice in the absence of IFN-a treatment, most notable were significantly upregulated IFN-responsive genes with IFN-responsive elements, such as CXCL10, GBP2, IFN regulatory factor 1 (IRF1), myxovirus (influenza virus) resistance 1 (MX1), OAS1G, 2 0 -5 0 oligoadenylate synthetase 2 (OAS2), protein kinase, IFNinducible double-stranded RNA-dependent (PRKR), STAT1, transporter 1, ATP-binding cassette, sub-family B (TAP1), guanylate nucleotide-binding protein 1 (GBP1) and IFN, a-inducible protein (G1P2), as well as a set of transcription factors involved in the transcriptional regulation of IFN-inducible genes, including STAT1, STAT2, IRF1 and IRF7. The IFN regulatory factors IRF-1 and IRF-7, which are known as transcriptional activators of the type I IFN genes, and Pit-1, Oct-1, and Oct-2 and the Caenorhabditis elegans gene unc-86 (POU) domain, class 2, transcription factor 1 (POU2f1), a transcriptional repressor, were up and downregulated, respectively, in NZB/W mice compared to lpr and BALB/c mice ( Table 3 ). The upregulated expression of many IFNresponsive genes and transcriptional activators of the type I IFN genes and ISGs in the splenic mononuclear cells from pre-autoimmune NZB/W mice in the absence of IFN-a treatment, reflected the comparative activation state of the IFN-a signaling pathway and an amplification loop of IFN-a production in the pre-autoimmune NZB/W mice. To confirm the expression data from oligonucleotide microarray studies, IRF7, MX1 and ISG20 were chosen and the expression were analyzed by real-time PCR; both of the methods detected the similar expression patterns of expression ( Figure 3 ).
Discussion
We have used oligonucleotide arrays to study the IFN-ainduced changes in mRNA expression in splenic mononuclear cells from pre-autoimmune NZB/W and MRL/ lpr lupus-prone mice to understand better the involvement of IFN-a in SLE pathogenesis at the genomic level. Three hours of IFN-a stimulation differentially increased expression of many signaling molecules within the signal transduction network, strongly suggesting the crosstalk among multiple signaling pathways, with a considerable number of signaling molecules shared by all three strains examined here, thus reflecting the important and core function of these genes and their associated signaling pathways in modulating the function of IFN-a.
A major finding of this report is an IFN-a signature in the splenic mononuclear cells of pre-autoimmune NZB/ W mice at 8 weeks age that is not established in 4-to 5-week-old lpr or normal BALB/c mice in the absence of ex vivo IFN-a treatment. Nine of 25 IFN-regulated genes that were increased significantly in NZB/W vs BALB/c and lpr mice prior to ex vivo IFN-a treatment were type I IFN-induced genes, including IRF7, MX1, MX2, IFIT2, IFIT4, PRKR, ISG20, G1P2 and OAS; 3 of 25, CXCL9, GBP2 and IGTP were preferentially induced by IFN-g and IFN-a may trigger the production of IFN-g. 2, 6 This may suggest that the primary driver for the IFNregulated gene-expression signature in the splenic mononuclear cells of pre-autoimmune NZB/W mice before ex vivo IFN-a treatment might be type I IFN. In accordance with a series of valuable microarray studies on human lupus demonstrating an IFN-a signature in SLE, our data imply that increased expression of IFN-a-regulated genes in the splenic mononuclear cells of pre-autoimmune NZB/W mice before ex vivo IFN-a treatment may present in a much earlier, pre-clinical stage of lupus development and require a genetically susceptible background. The NZB/W and the MRL/lpr strain mice are two classic spontaneous lupus-prone models that share severe systemic autoimmunity and immune complex-mediated fatal glomerulonephritis. Lupus susceptibility in the NZB/W model is predominantly due to genetic interactions between alleles of H2 z from NZB and H2 d from NZW. In addition to the MHC loci, several lupussusceptibility loci derived from the NZB and NZW strains have been identified, including Sle1-Sle6, Nba1-Nba4, Nwa1-Nwa2 and Lbw1-Lbw8. [38] [39] [40] [41] [42] However, the lpr mutation in an MRL susceptibility background is a key element in the penetrance of disease pathogenesis in the MRL/lpr strain.
The significant overexpression of IP10 in the splenic mononuclear cells of pre-autoimmune NZB/W mice in the absence of IFN-a treatment appears to be mediated, at least in part, by a Toll-like receptor signaling pathway secondary to IFN-b production 43, 44 and is controlled at the transcriptional level by the transcription factors IFNstimulated gene factor 3 complex (ISGF3), IRF3, nuclear factor-kB (NF-kB). 45, 46 The stimuli remain to be defined; however, IFN-a was reported expressing at low levels in normal or axenic mice. 47 Rapid stimulation of the Tolllike receptor causes IRF3 activation, IFN-b synthesis and signal transduction through the type I IFNAR. In turn, IFNAR signal transduction increases IRF7 expression, which is an IFN-a/b-inducible gene. Increased expression and activation of IRF7 leads to enhanced expression of IFN-b and many of the IFN-a genes. Accordingly, a significant upregulation of TLR7, ISGs and transcriptional activators of the type I IFN genes and ISGs (IRF7, IRF1, STAT1, STAT2) in the splenic mononuclear cells derived from preautoimmune NZB/W mice in the absence of IFN-a treatment suggested that an amplification loop of type I IFN production was in operation.
In this report, we have identified a set of significantly overexpressed genes induced by IFN-a in the splenic mononuclear cells of NZB/W mice compared to BALB/c and MRL/lpr mice after 3 h treatment including MMP-13 and CITED2. The cytokine-activated JAK-STAT pathway is perhaps the most extensively studied IFN-dependent signaling pathway. In this pathway, cytokines bind to their cognate receptors and initiate a signal resulting in the activation of JAK and other signal transduction and transcriptional activator proteins, leading to the synthesis of target genes. Activation of the JAK-STAT signaling pathway can be downregulated by the suppressor of cytokine signaling (SOCS) proteins. MMP-13 is one of a group of zinc-dependent matrix metalloprotei- These genes were selected because their difference in expression was significant (Po0.01) with X2-fold change in the splenic mononuclear cells of 8-week-old NZB/NZW mice as compared to the normal 8-week-old BALB/c and 4 to 5-week-old lpr mice.
Global analysis of lupus mice treated by IFN-a in vitro Q Lu et al nases (MMPs). Many MMPs possess transcription factorbinding motifs such as AP1, AP2, NF-kB, PEA3, Sp1 and STAT elements in their 5 0 -flanking regulatory DNA sequences. 48, 49 As a member of the CITED family of transcriptional co-activators, the promoter of CITED2 contains multiple STAT-binding sites, consistent with its responsiveness to different cytokines. 50, 51 In addition, crosstalk between the IFN-a system and a member of the nuclear hormone receptor-peroxisome proliferator-activated receptor a (PPARa) is suggested by CITED2, which is a known PPARa co-activator. 52 The PPARs have been implicated in a wide range of biological processes, including cell growth, lipid homeostasis, apoptosis and inflammation. 53 Notably, an additional transcriptional co-activator, NMI, which interacts with all STATs (except STAT2) and potentiates their association with the coactivators CBP/p300 54 was upregulated in all three strains by 3 h IFN-a stimulation and significantly overexpressed in MRL/lpr and BALB/c mice at 3 h time point. Interestingly, NMI and CITED2 exhibited different responses to IFN-a treatment in two lupus-prone strains.
Dysregulation of chemokine and cytokine expression has a complex role in the pathogenesis of autoimmune diseases. It has been reported through a survey of the serologic proteome in human SLE that a set of IFNregulated inflammatory chemokines had highly coordinated upregulation and their levels correlated strongly with clinical and laboratory measures of disease activity, thus, may function as biomarkers for active human SLE. 55 In this study, the complex interactions of cytokines and chemokines underlying IFN-a treatment were suggested. Of a panel of chemokines and cytokines overexpressed in NZB/W mice after IFN-a treatment in vitro, the disparity in the basal and stimulated level of CXCL10 compared to the other two strains was striking. CXCL10 can be expressed locally in response to inflammatory and antigenic stimuli and may amplify subsequent tissue reactions by virtue of activating and selective chemotactic activities on activated CD4 þ lymphocytes, signaling through the chemokine receptor CXCR3. Therefore, CXCL10 might be a critical mediator of CD4 þ lymphocyte migration and involved in CD4 þ Tcell-dependent immune-responses 56 underlying the IFNa treatment process in NZB/W mice.
The NZB/W model is generally considered to most closely reflect the properties of human SLE, in that this strain exhibits a strong female gender bias in susceptibility. This female gender bias is thought to be mediated, in part, through estrogen and prolactin. 57 Studies in male and female NZB/W lupus-prone mice demonstrated that hyperprolactinemia induced by transplantation of pituitary glands leads to disease exacerbation and early mortality. 58 Overexpression of human PTTG1 C-terminal peptide, which contains PXXP motifs (proline-prolineserine-proline), has been reported to suppress prolactin expression in rat prolactin (rPRL)-and GH-secreting GH3 cells. 59 The significant difference in expression level of PTTG1 in NZB/W mice compared to lpr and BALB/c mice after 3 h IFN-a treatment in vitro might provide a potential subcellular therapeutic target for PRL hypersecretion.
In summary, using microarray technology, we have determined the ex vivo IFN-a response of splenic mononuclear cells derived from pre-autoimmune NZB/W and MRL/lpr lupus-prone mice and BALB/c mice at the genomic level and may therefore gain a unique angle of insight into the genetic component of IFN-a involved in the pathogenesis of SLE. Study on the spontaneous lupus-predisposition models at the pre-autoimmune stage may permit characterization of immunologic abnormalities before, during and after disease development. In this study, we have identified an IFN-a signature in pre-autoimmune NZB/W that is not found in MRL/lpr mice in the absence of IFN-a treatment, suggesting that IFN-a signature may be an early immunologic abnormality required by the genetic susceptibility background. At the genomic level, we have observed different downstream effects on cell proliferation and inflammation in the splenic mononuclear cells from two lupus-prone models by short-term in vitro exposure to IFN-a. These results confirmed the heterogeneous nature of SLE and suggested the requirement of the genetic susceptibility background that contributed to the effects of IFN-a on the pathogenesis of SLE.
Materials and methods

Mice
Two NZB/W and MRL/lpr lupus-prone mouse models were used for IFN-a-induced gene-expression profiling studies. BALB/c mice were used as controls. Female MRL/lpr and normal BALB/c mice were purchased from the Shanghai Laboratory Animal Center, Chinese Academy of Science (Shanghai, China). Female NZB/W mice were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China). All mice were maintained under specific pathogen-free conditions in an environmentally controlled clean room at the Animal Center of Medical College, Shanghai JiaoTong University. Splenocytes were obtained from individual NZB/W, MRL/lpr and BALB/c mice, respectively, when both of NZB/W and BALB/c mice were 2 months of age and MRL/lpr mice were 4-5 weeks of age. Sera were collected for measurement of IgG antibodies to dsDNA.
Preparation, culture and IFN-a treatment of splenic mononuclear cells Splenocytes from each mouse were obtained by gently disrupting the spleen between sintered glass slides in RPMI 1640 medium (Gibco-BRL, Invitrogen Corp., Carlsbad, CA, USA) containing 10% fetal calf serum (Hyclone, Logan, UT, USA), supplemented with the antibiotics penicillin (100 U ml
À1
) and streptomycin (100 U ml À1 ). After contaminating RBCs were removed by treating cell suspensions with a 5 min exposure to 5 ml per spleen of erythrocyte-lysing buffer (0.144 M NH 4 Cl, 17 mM Tris pH 7.2), splenocytes were washed twice, and resuspended at 10 8 cells in 1-2 ml of phosphate-buffered saline with 3% fetal calf serum and 2 mM ethylenediamine tetraacetic acid. Splenic mononuclear cells from each mouse were isolated using NycoPrep 1.077 A (AxisShield, Oslo, Norway) and independently incubated at 2 Â 10 6 cells ml À1 of complete RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotics in the absence or presence of 1 Â 10 3 IU ml À1 of recombinant mouse IFN a A (PBL Biomedical Laboratories, Piscataway, NJ, USA) for 3, 6 and 24 h. The splenic mononuclear cells were harvested and cell viability was determined by trypan blue-dye exclusion.
Total RNA extraction, complementary RNA preparation and hybridization Total RNA from untreated splenic mononuclear cells and cells stimulated for 3, 6 and 24 h with IFN-a from the three strains was extracted using the RNeasy mini kit with on-column DNase digestion (Qiagen Inc., Valencia, CA, USA). To avoid fluctuation between individuals, total RNA were pooled from five (NZB/W) and five (MRL/lpr) lupus-prone mice and five normal BALB/c mice, at each time point (0, 3, 6 and 24 h), respectively. Biotinylated cRNA was prepared using the Illumina TotalPrep RNA Amplification kit (Ambion Inc., Austin, TX, USA) according to the manufacturer's instruction manual. Briefly, about 50 ng ml À1 total RNA in 11 ml nuclease-free water per sample was reverse-transcribed into first-strand cDNA with an oligo(dT) primer bearing a T7 promoter using Array-Script reverse transcriptase (RT). After the second-strand synthesis and clean-up, biotinylated cRNA was generated by in vitro transcription with T7 RNA polymerase supplemented with biotin uridine triphosphate. The Sentrix Mouse-6 Expression BeadChip (Illumina Inc., San Diego, CA, USA) represents a set of six individual Genechip probe arrays, each containing approximately 36 400 oligonucleotide probe sets representing a murine genome. The Sentrix Mouse-6 Expression BeadChips were then hybridized, washed and scanned on an Illumina Sherlock Scanner according to the manufacturer's protocol at the National Engineering Center for Biochip in Shanghai.
Data analysis
For the comparison between a group of samples (referred to as the condition group) to a reference group, 'Differential Expression assay' was done using the 'Illumina custom' error model, the 'rank invariant' data normalization method and several filters including diff score, detection level and fold change which defaulted by the BeadStudio package. P-values can be calculated using the following approach:
Diff Score ¼ 10 sgn ðm cond À m ref Þ log 10 ðPÞ where P is the statistical confidence, and m cond and m ref are the average intensity of condition and reference sample, respectively; Genes with 'DffScore 420' were selected as P-values o0.01. Detection is defined as: 1-P-values computed from the background model characterizing the chance that the target sequence signal was distinguishable from the negative controls. The default setting of 'detection level' is 40.99 (signal intensity 423.5). Fold changes for gene expression were calculated, and genes with X1.5-fold change in gene expression were selected for further characterization. In this microarray system, system controls cover every aspect of the array experiment from the biological specimen (housekeeping controls), to sample labeling (RNA spike), to hybridization (Cy3-Labeles hybridization controls, low/high stringency hybridization controls), to signal generation (Biotin control) and negative controls.
Hierarchical clustering analysis and visualization in tree view were performed in Hierarchical Clustering Explore (HCE) 3.0 (Human-Computer Interaction Lab, University of Maryland, College Park, MD, USA). Input data were first standardized row by row (that is the deviation from the mean was calculated and then the deviation was divided by s.d.) followed by hierarchical clustering (combination of clustering parameters of Average Linkage Method and Personal Correlation Coefficient Similarity and Distance Measure).
Real-time PCR
Total RNA (100 ng) was processed directly to cDNA by reverse transcription with Superscript II (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol in a total volume of 20 ml. All PCR primers (Table 4) were designed using software OLIGO 6 using published sequence data from the NCBI database. Primers were synthesized by Shanghai Sangon Biological Engineering Technology. cDNA were amplified with the SYBR Premix Ex Taq (TaKaRa, Dalian). PCR amplification reactions contained 0.5-1 ml cDNA, 2.5 ml of SyBR premix ExTaq (2 Â ), 0.1 ml of Rox Reference Dye (50 Â ) and 0.1 ml of each of the specific primers. Primer concentrations in the final volume of 5 ml were 200 nM, respectively. All reactions were performed in triplicate in an ABI PRISM 7700 system and the thermal cycling conditions were: 15 s at 951C followed by 40 cycles of 951C for 5 s, and 601C for 30 s. Purity of the amplified PCR products was determined by a heat-dissociation protocol to enable detection of non-specific amplification. We used the expression of b-actin in splenic mononuclear cells to normalize the expression data of each of the genes. TGTCACCAAACGAGGACTAA  AGTTTCAGCCATGTTCTTTC  CXCL10  ACGAACTTAACCACCATCTTCC  TCTTCCATATACAATGCAAAGCA  IL-15  AGTGACTTTCATCCCAGTTG  GAGCACGTTTCTTACTGTTTC  CDKN1A  CTGTCTTGCACTCTGGTGTC  CGCTTGGAGTGATAGAAATC  CITED2  CCGTTCTGGATCAGGAAAAGT  CACTGACGACATTCCACACC  MX1  CTGAGGGCTCTGGGTGT  GTAACAATACCACTGCCTCTG  IRF7  CCTGATCCTGGTGAAGCTGG  TGGGAGTTGGGATTCTGAGTC  CCL3  TTCTCTGTACCATGACACTCTGC  CGTGGAATCTTCCGGCTGTAG  PTTG1  GCTAGAAAGGAAGCGCAGAA  TAACAAACAGGCGGCAATTC  ISG20 GCAGTACTACAGCCGAGTGT TCGCTGAGAGATTTTGTAGAG Primers were designed using software OLIGO6 using sequence data from the NCBI database.
